Exacerbations in cystic fibrosis·1: Epidemiology and pathogenesis

Thorax

Volumn 62, Issue 4, 2007, Pages 360-367

  Goss, Christopher H ^a   Burns, Jane L ^b  

^a UNIVERSITY OF WASHINGTON MEDICAL CENTER   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE DERIVATIVE; ANTIBIOTIC AGENT; AZTREONAM; BETA LACTAM; CARBOPENEM; CEFOPERAZONE; CEFTAZIDIME; CHLORAMPHENICOL; CIPROFLOXACIN; COTRIMOXAZOLE; IMIPENEM; MEROPENEM; MINOCYCLINE; PIPERACILLIN; QUINOLONE DERIVATIVE; TICARCILLIN; TIMENTIN; TOBRAMYCIN; TRANSMEMBRANE CONDUCTANCE REGULATOR; UNCLASSIFIED DRUG; VANCOMYCIN;

ARTIFICIAL VENTILATION; CLINICAL TRIAL; DIAGNOSTIC PROCEDURE; DISEASE EXACERBATION; DRUG POTENTIATION; HUMAN; INTENSIVE CARE; LUNG FIBROSIS; MORTALITY; PATHOGENESIS; PRIORITY JOURNAL; PROGNOSIS; QUALITY OF LIFE; REVIEW; SURVIVAL RATE;

ACUTE DISEASE; ADOLESCENT; ADULT; AGE DISTRIBUTION; AGED; BACTERIA; BRONCHI; CHILD; CHILD, PRESCHOOL; CYSTIC FIBROSIS; HUMANS; INFANT; INFANT, NEWBORN;

EID: 34147215995     PISSN: 00406376     EISSN: None     Source Type: Journal    
DOI: 10.1136/thx.2006.060889     Document Type: Review

References (119)

1. Ferkol T, Rosenfeld M, Milla CE. Cystic fibrosis pulmonary exacerbations. J Pediatr 2006;148:259-64.
2. Boucher RC. New concepts of the pathogenesis of cystic fibrosis lung disease. Eur Respir J 2004;23:146-58.
3. Randell SH, Boucher RC. Effective mucus clearance is essential for respiratory health. Am J Respir Cell Mol Biol 2006;35:20-8.
4. Mall M, Grubb BR, Harkema JR, et al. Increased airway epithelial Na+ absorption produces cystic fibrosis-like lung disease in mice. Nat Med 2004;10:487-93.
5. Donaldson SH, Bennett WD, Zeman KL, et al. Mucus clearance and lung function in cystic fibrosis with hypertonic saline. N Engl J Med 2006;354:241-50.
6. Elkins MR, Robinson M, Rose BR, et al. A controlled trial of long-term inhaled hypertonic saline in patients with cystic fibrosis. N Engl J Med 2006;354:229-40.
7. Joo NS, Irokawa T, Wu JV, et al. Absent secretion to vasoactive intestinal peptide in cystic fibrosis airway glands. J Biol Chem 2002;277:50710-5.
8. Joo NS, Lee DJ, Winges KM, et al. Regulation of antiprotease and antimicrobial protein secretion by airway submucosal gland serous cells. J Biol Chem 2004;279:38854-60.
9. Joo NS, Irokawa T, Robbins RC, et al. Hyposecretion, not hyperabsorption, is the basic defect of cystic fibrosis airway glands. J Biol Chem 2006;281:7392-8.
10. Hiatt PW, Grace SC, Kozinetz CA, et al. Effects of viral lower respiratory tract infection on lung function in infants with cystic fibrosis. Pediatrics 1999;103:619-26.
11. Piedra PA, Grace S, Jewell A, et al. Purified fusion protein vaccine protects against lower respiratory tract illness during respiratory syncytial virus season in children with cystic fibrosis. Pediatr Infect Dis J 1996;15:23-31.
12. Piedra PA, Cron SG, Jewell A, et al. Immunogenicity of a new purified fusion protein vaccine to respiratory syncytial virus: a multi-center trial in children with cystic fibrosis. Vaccine 2003;21:2448-60.
13. Regelmann WE, Elliott GR, Warwick WJ, et al. Reduction of sputum Pseudomonas aeruginosa density by antibiotics improves lung function in cystic fibrosis more than do bronchodilators and chest physiotherapy alone. Am Rev Respir Dis 1990;141:914-21.
14. Smith AL, Redding G, Doershuk C, et al. Sputum changes associated with therapy for endobronchial exacerbation in cystic fibrosis. J Pediatr 1988;112:547-54.
15. Wat D, Doull I. Respiratory virus infections in cystic fibrosis. Paediatr Respir Rev 2003;4:172-7.
16. van Ewijk BE, van der Zalm MM, Wolfs TF, et al. Viral respiratory infections in cystic fibrosis. J Cyst Fibros 2005;4(Suppl 2):31-6.
17. Ramsey BW, Pepe MS, Quan JM, et al. Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. Cystic Fibrosis Inhaled Tobramycin Study Group. N Engl J Med 1999;340:23-30.
18. Aaron SD, Ramotar K, Ferris W, et al. Adult cystic fibrosis exacerbations and new strains of Pseudomonas aeruginosa. Am J Respir Crit Care Med 2004;169:811-5.
19. Konstan MW, Walenga RW, Hilliard KA, et al. Leukotriene B4 markedly elevated in the epithelial lining fluid of patients with cystic fibrosis. Am Rev Respir Dis 1993;148:896-901.
20. Konstan MW, Hilliard KA, Norvell TM, et al. Bronchoalveolar lavage findings in cystic fibrosis patients with stable, clinically mild lung disease suggest ongoing infection and inflammation. Am J Respir Crit Care Med 1994;150:448-54.
21. Bonfield TL, Panuska JR, Konstan MW, et al. Inflammatory cytokines in cystic fibrosis lungs. Am J Respir Crit Care Med 1995;152:2111-8.
22. Sagel SD, Kapsner R, Osberg I, et al. Airway inflammation in children with cystic fibrosis and healthy children assessed by sputum induction. Am J Respir Crit Care Med 2001;164:1425-31.
23. Ordonez CL, Henig NR, Mayer-Hamblett N, et al. Inflammatory and microbiologic markers in induced sputum after intravenous antibiotics in cystic fibrosis. Am J Respir Crit Care Med 2003;168:1471-5.
24. Colombo C, Costantini D, Rocchi A, et al. Cytokine levels in sputum of cystic fibrosis patients before and after antibiotic therapy. Pediatr Pulmonol 2005;40:15-21.
25. Fuchs HJ, Borowitz DS, Christiansen DH, et al. Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. The Pulmozyme Study Group. N Engl J Med 1994;331:637-42.
26. Gibson RL, Emerson J, McNamara S, et al. Significant microbiological effect of inhaled tobramycin in young children with cystic fibrosis. Am J Respir Crit Care Med 2003;167:841-9.
27. Saiman L, Marshall BC, Mayer-Hamblett N, et al. Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized controlled trial. JAMA 2003;290:1749-56.
28. Ramsey BW, Boat TF. Outcome measures for clinical trials in cystic fibrosis. Summary of a Cystic Fibrosis Foundation consensus conference. J Pediatr 1994;124:177-92.
29. Marshall BC. Pulmonary exacerbations in cystic fibrosis: it's time to be explicit! Am J Respir Crit Care Med 2004;169:781-2.
30. Cystic Fibrosis Foundation. Microbiology and infectious disease in cystic fibrosis: V (Section 1). Bethesda, MD: Cystic Fibrosis Foundation, 1994.
31. Johnson C, Butler SM, Konstan MW, et al. Factors influencing outcomes in cystic fibrosis: a center-based analysis. Chest 2003;123:20-7.
32. Dakin C, Henry RL, Field P, et al. Defining an exacerbation of pulmonary disease in cystic fibrosis. Pediatr Pulmonol 2001;31:436-42.
33. Rosenfeld M, Emerson J, Williams-Warren J, et al. Defining a pulmonary exacerbation in cystic fibrosis. J Pediatr 2001;139:359-65.
34. Rabin HR, Butler SM, Wohl ME, et al. Pulmonary exacerbations in cystic fibrosis. Pediatr Pulmonol 2004;37:400-6.
35. Wilkinson TM, Donaldson GC, Hurst JR, et al. Early therapy improves outcomes of exacerbations of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2004;169:1298-303.
36. Ellaffi M, Vinsonneau C, Coste J, et al. One-year outcome after severe pulmonary exacerbation in adults with cystic fibrosis. Am J Respir Crit Care Med 2005;171:158-64.
37. Texereau J, Jamal D, Choukroun G, et al. Determinants of mortality for adults with cystic fibrosis admitted in Intensive Care Unit: a multicenter study. Respir Res 2006;7:14.
38. Dobbin G, Milross MA, Piper AJ, et al. Sequential use of oxygen and bi-level ventilation for respiratory failure in cystic fibrosis. J Cyst Fibros 2004;3:237-42.
39. Sood N, Paradowski U, Yankaskas JR. Outcomes of intensive care unit care in adults with cystic fibrosis. Am J Respir Crit Care Med 2001;163:335-8.
40. Vedam H, Moriarty C, Torzillo PJ, et al. Improved outcomes of patients with cystic fibrosis admitted to the intensive care unit. J Cyst Fibros 2004;3:8-14.
41. Slieker MG, van Gestel JP, Heijemnan HG, et al. Outcome of assisted ventilation for acute respiratory failure in cystic fibrosis. Intensive Care Med 2006;32:754-8.
42. Liou TG, Adler FR, Fitzsimmons SC, et al. Predictive 5-year survivorship model of cystic fibrosis. Am J Epidemiol 2001;153:345-52.
43. Liou TG, Adler FR, Cahill BC, et al. Survival effect of lung transplantation among patients with cystic fibrosis. JAMA 2001;286:2683-9.
44. Mayer-Hamblett N, Rosenfeld M, Emerson J, et al. Developing cystic fibrosis lung transplant referral criteria using predictors of 2-year mortality. Am J Respir Crit Care Med 2002;166:1550-5.
45. Liou TG, Adler FR, Huang D. Use of lung transplantation survival models to refine patient selection in cystic fibrosis. Am J Respir Crit Care Med 2005;171:1053-9.
46. Emerson J, Rosenfeld M, McNamara S, et al. Pseudomonas aeruginosa and other predictors of mortality and morbidity in young children with cystic fibrosis. Pediatr Pulmonol 2002;34:91-100.
47. Marshall BC, Butler SM, Stoddard M, et al. Epidemiology of cystic fibrosis-related diabetes. J Pediatr 2005;146:681-7.
48. Britto MT, Kotagal UR, Hornung RW, et al. Impact of recent pulmonary exacerbations on quality of life in patients with cystic fibrosis. Chest 2002;121:64-72.
49. Dobbin CJ, Bartlett D, Melehan K, et al. The effect of infective exacerbations on sleep and neurobehavioral function in cystic fibrosis. Am J Respir Crit Care Med 2005;172:99-104.
50. Goss CH, Otto K, Aitken ML, et al. Detecting Stenotrophomonas maltophilia does not reduce survival of patients with cystic fibrosis. Am J Respir Crit Care Med 2002;166:356-61.
51. Goss CH, Rubenfeld GD, Otto K, et al. The effect of pregnancy on survival in women with cystic fibrosis. Chest 2003;124:1460-8.
52. Goss CH, Mayer-Hamblett N, Aitken ML, et al. Association between Stenotrophomonas maltophilia and lung function in cystic fibrosis. Thorax 2004;59:955-9.
53. Schechter MS, Shelton BJ, Margolis PA, et al. The association of socioeconomic status with outcomes in cystic fibrosis patients in the United States. Am J Respir Crit Care Med 2001;163:1331-7.
54. Goss CH, Newsom SA, Schildcrout JS, et al. Effect of ambient air pollution on pulmonary exacerbations and lung function in cystic fibrosis. Am J Respir Crit Care Med 2004;169:816-21.
55. Brody AS, Sucharew H, Campbell JD, et al. Computed tomography correlates with pulmonary exacerbations in children with cystic fibrosis. Am J Respir Crit Care Med 2005;172:1128-32.
56. Smith JA, Owen EC, Jones AM, et al. Objective measurement of cough during pulmonary exacerbations in adults with cystic fibrosis. Thorax 2006;61:425-9.
57. Kiska DL, Kerr A, Jones MC, et al. Accuracy of four commercial systems for identification of Burkholderia cepacia and other gram-negative nonfermenting bacilli recovered from patients with cystic fibrosis. J Clin Microbiol 1996;34:886-91.
58. Shelly DB, Spilker T, Gracely EJ, et al. Utility of commercial systems for identification of Burkholderia cepacia complex from cystic fibrosis sputum culture. J Clin Microbiol 2000;38:3112-5.
59. Saiman L, Burns JL, Larone D, et al. Evaluation of MicroScan Autoscan for identification of Pseudomonas aeruginosa isolates from cystic fibrosis patients. J Clin Microbiol 2003;41:492-4.
60. Burns JL, Saiman L, Whittier S, et al. Comparison of two commercial systems (Vitek and MicroScan-WalkAway) for antimicrobial susceptibility testing of Pseudomonas aeruginosa isolates from cystic fibrosis patients. Diagn Microbiol Infect Dis 2001;39:257-60.
61. Wong K, Roberts MC, Owens L, et al. Selective media for the quantitation of bacteria in cystic fibrosis sputum. J Med Microbiol 1984;17:113-9.
62. Carson LA, Tablan OC, Cusick LB, et al. Comparative evaluation of selective media for isolation of Pseudomonas cepacia from cystic fibrosis patients and environmental sources. J Clin Microbiol 1988;26:2096-100.
63. Henry DA, Campbell ME, LiPuma JJ, et al. Identification of Burkholderia cepacia isolates from patients with cystic fibrosis and use of a simple new selective medium. J Clin Microbiol 1997;35:614-9.
64. Burns JL, Emerson J, Stapp JR, et al. Microbiology of sputum from patients at cystic fibrosis centers in the United States. Clin Infect Dis 1998;27:158-63.
65. Whitby PW, Carter KB, Burns JL, et al. Identification and detection of Stenotrophomonas maltophilia by rRNA- directed PCR. J Clin Microbiol 2000;38:4305-9.
66. Liu L, Coenye T, Burns JL, et al. Ribosomal DNA-directed PCR for identification of Achromobacter (Alcaligenes) xylosoxidans recovered from sputum samples from cystic fibrosis patients. J Clin Microbiol 2002;40:1210-3.
67. Coenye T, Vandamme P, LiPuma JJ. Infection by Ralstonia species in cystic fibrosis patients: identification of R pickettii and R mannitolilytica by polymerase chain reaction. Emerg Infect Dis 2002;8:692-6.
68. Qin X, Emerson J, Stapp J, et al. Use of real-time PCR with multiple targets to identify Pseudomonas aeruginosa and other nonfermenting gram-negative bacilli from patients with cystic fibrosis. J Clin Microbiol 2003;41:4312-7.
69. Armstrong DS, Grimwood K, Carlin JB, et al. Bronchoalveolar lavage or oropharyngeal cultures to identify lower respiratory pathogens in infants with cystic fibrosis. Pediatr Pulmonol 1996;21:267-75.
70. Rosenfeld M, Emerson J, Accurso F, et al. Diagnostic accuracy of oropharyngeal cultures in infants and young children with cystic fibrosis. Pediatr Pulmonol 1999;28:321-8.
71. Kabra SK, Alok A, Kapil A, et al. Can throat swab after physiotherapy replace sputum for identification of microbial pathogens in children with cystic fibrosis? Indian J Pediatr 2004;71:21-3.
72. De BK, Alifier M, Vandeputte S. Sputum induction in young cystic fibrosis patients. Eur Respir J 2000;16:91-4.
73. Henig NR, Tonelli MR, Pier MV, et al. Sputum induction as a research tool for sampling the airways of subjects with cystic fibrosis. Thorax 2001;56:306-11.
74. Suri R, Marshall U, Wallis C, et al. Safety and use of sputum induction in children with cystic fibrosis. Pediatr Pulmonol 2003;35:309-13.
75. Ho SA, Ball R, Morrison U, et al. Clinical value of obtaining sputum and cough swab samples following inhaled hypertonic saline in children with cystic fibrosis. Pediatr Pulmonol 2004;38:82-7.
76. Armstrong DS, Grimwood K, Carlin JB, et al. Lower airway inflammation in infants and young children with cystic fibrosis. Am J Respir Crit Care Med 1997;156:1197-204.
77. Lyczak JB, Cannon CL, Pier GB. Lung infections associated with cystic fibrosis. Clin Microbiol Rev 2002;15:194-222.
78. Firzsimmons SC. The changing epidemiology of cystic fibrosis. J Pediatr 1993;122:1-9.
79. Ratjen F, Comes G, Paul K, et al. Effect of continuous antistaphylococcal therapy on the rate of P aeruginosa acquisition in patients with cystic fibrosis. Pediatr Pulmonol 2001;31:13-6.
80. Stutman HR, Lieberman JM, Nussbaum E, et al. Antibiotic prophylaxis in infants and young children with cystic fibrosis: a randomized controlled trial. J Pediatr 2002;140:299-305.
81. Rosenfeld M, Gibson RL, McNamara S, et al. Early pulmonary infection, inflammation, and clinical outcomes in infants with cystic fibrosis. Pediatr Pulmonol 2001;32:356-66.
82. Barker AF. Bronchiectasis. N Engl J Med 2002;346:1383-93.
83. Cystic Fibrosis Foundation. Patient Registry 2004 Annual Data Report, 1-2.Bethesda, Maryland, 2005.
84. Demko CA, Byard PJ, Davis PB. Gender differences in cystic fibrosis: Pseudomonas aeruginosa infection. J Clin Epidemiol 1995;48:1041-9.
85. Nixon GM, Armstrong DS, Carzino R, et al. Clinical outcome after early Pseudomonas aeruginosa infection in cystic fibrosis. J Pediatr 2001;138:699-704.
86. Kosorok MR, Zeng L, West SE, et al. Acceleration of lung disease in children with cystic fibrosis after Pseudomonas aeruginosa acquisition. Pediatr Pulmonol 2001;32:277-87.
87. Li Z, Kosorok MR, Farrell PM, et al. Longitudinal development of mucoid Pseudomonas aeruginosa infection and lung disease progression in children with cystic fibrosis. JAMA 2005;293:581-8.
88. Hancock RE, Mutharia LM, Chan L, et al. Pseudomonas aeruginosa isolates from patients with cystic fibrosis: a class of serum-sensitive, nontypable strains deficient in lipopolysaccharide O side chains. Infect Immun 1983;42:170-7.
89. Luzar MA, Montie TC. Avirulence and altered physiological properties of cystic fibrosis strains of Pseudomonas aeruginosa. Infect Immun 1985;50:572-6.
90. Ernst RK, Yi EC, Guo L, et al. Specificlipopolysaccharide found in cystic fibrosis airway Pseudomonas aeruginosa. Science 1999;286:1561-5.
91. Thomas SR, Ray A, Hodson ME, et al. Increased sputum amino acid concentrations and auxotrophy of Pseudomonas aeruginosa in severe cystic fibrosis lung disease. Thorax 2000;55:795-7.
92. Burns JL, Gibson RL, McNamara S, et al. Longitudinal assessment of Pseudomonas aeruginosa in young children with cystic fibrosis. J Infect Dis 2001;183:444-52.
93. Drenkard E, Ausubel FM. Pseudomonas biofilm formation and antibiotic resistance are linked to phenotypic variation. Nature 2002;416:740-3.
94. Thomassen MJ, Demko CA, Klinger JD, et al. Pseudomonas cepacia colonization among patients with cystic fibrosis. A new opportunist. Am Rev Respir Dis 1985;131:791-6.
95. Isles A, Maclusky I, Corey M, et al. Pseudomonas cepacia infection in cystic fibrosis: an emerging problem. J Pediatr 1984;104:206-10.
96. LiPuma JJ. Update on the Burkholderia cepacia complex. Curr Opin Pulm Med 2005;11:528-33.
97. LiPuma JJ, Spilker T, Gill LH, et al. Disproportionate distribution of Burkholderia cepacia complex species and transmissibility markers in cystic fibrosis. Am J Respir Crit Care Med 2001;164:92-6.
98. Biddick R, Spilker T, Martin A, et al. Evidence of transmission of Burkholderia cepacia, Burkholderia multivorans and Burkholderia dolosa among persons with cystic fibrosis. FEMS Microbiol Lett 2003;228:57-62.
99. Kidd TJ, Bell SC, Coulter C. Genomovar diversity amongst Burkholderia cepacia complex isolates from an Australian adult cystic fibrosis unit. Eur J Clin Microbiol Infect Dis 2003;22:434-7.
100. Cunha MV, Leitao JH, Mahenthiralingam E, et al. Molecular analysis of Burkholderia cepacia complex isolates from a Portuguese cystic fibrosis center: a 7-year study. J Clin Microbiol 2003;41:4113-20.
101. Mahenthiralingam E, Vandamme P, Campbell ME, et al. Infection with Burkholderia cepacia complex genomovars in patients with cystic fibrosis: virulent transmissible strains of genomovar III can replace Burkholderia multivorans. Clin Infect Dis 2001;33:1469-75.
102. Kalish LA, Waltz DA, Dovey M, et al. Impact of Burkholderia dolosa on lung function and survival in cystic fibrosis. Am J Respir Crit Care Med 2006;173:421-5.
103. Tan K, Canway SP, Brownlee KG, et al. Alcaligenes infection in cystic fibrosis. Pediatr Pulmonol 2002;34:101-4.
104. Burns JL, Saiman L, Whittier S, et al. Comparison of agar diffusion methodologies for antimicrobial susceptibility testing of Pseudomonas aeruginosa isolates from cystic fibrosis patients. J Clin Microbiol 2000;38:1818-22.
105. Ciofu O, Giwercman B, Pedersen SS, et al. Development of antibiotic resistance in Pseudomonas aeruginosa during two decades of antipseudomonal treatment at the Danish CF Center. APMIS 1994;102:674-80.
106. Taccetti G, Campana S, Marianelli L. Multiresistant non-fermentative gram-negative bacteria in cystic fibrosis patients: the results of an Italian multicenter study. Italian Group for Cystic Fibrosis microbiology. Eur J Epidemiol 1999;15:85-8.
107. Saiman L, Mehar F, Niu WW, et al. Antibiotic susceptibility of multiply resistant Pseudomonas aeruginosa isolated from patients with cystic fibrosis, including candidates for transplantation. Clin Infect Dis 1996;23:532-7.
108. Lang BJ, Aaron SD, Ferris W, et al. Multiple combination bactericidal antibiotic testing for patients with cystic fibrosis infected with multiresistant strains of Pseudomonas aeruginosa. Am J Respir Crit Care Med 2000;162:2241-5.
109. Aaron SD, Vandemheen KL, Ferris W, et al. Combination antibiotic susceptibility testing to treat exacerbations of cystic fibrosis associated with multiresistant bacteria: a randomised, double-blind, controlled clinical trial. Lancet 2005;366:463-71.
110. Smith AL, Fiel SB, Mayer-Hamblett N, et al. Susceptibility testing of Pseudomonas aeruginosa isolates and clinical response to parenteral antibiotic administration: lack of association in cystic fibrosis. Chest 2003;123:1495-502.
111. Aaron SD, Ferris W, Ramotar K, et al. Single and combination antibiotic susceptibilities of planktonic, adherent, and biofilm-grown Pseudomonas aeruginosa isolates cultured from sputa of adults with cystic fibrosis. J Clin Microbiol 2002;40:4172-9.
112. Moskowitz SM, Foster JM, Emerson J, et al. Clinically feasible biofilm susceptibility assay for isolates of Pseudomonas aeruginosa from patients with cystic fibrosis. J Clin Microbiol 2004;42:1915- 22.
113. Appelbaum PC. The emergence of vancomycin-intermediate and vancomycin-resistant Staphylococcus aureus. Clin Microbiol Infect 2006;12(Suppl 1):16-23.
114. Moore RA, Hancock RE. Involvement of outer membrane of Pseudomonas cepacia in aminoglycoside and polymyxin resistance. Antimicrob Agents Chemother 1986;30:923-6.
115. Lewin C, Doherty C, Govan J. In vitro activities of meropenem, PD 127391, PD 131628, ceftazidime, chloramphenicol, co-trimoxazole, and ciprofloxacin against Pseudomonas cepacia. Antimicrob Agents Chemother 1993;37:123-5.
116. Aaron SD, Ferris W, Henry DA, et al. Multiple combination bactericidal antibiotic testing for patients with cystic fibrosis infected with Burkholderia cepacia. Am J Respir Crit Care Med 2000;161:1206-12.
117. Burns JL, Saiman L. Burkholderia cepacia infections in cystic fibrosis. Pediatr Infect Dis J 1999;18:155-6.
118. Krueger TS, Clark EA, Nix DE. In vitro susceptibility of Stenotrophomonas maltophilia to various antimicrobial combinations. Diagn Microbiol Infect Dis 2001;41:71-8.
119. Saiman L, Chen Y, Tabibi S, et al. Identification and antimicrobial susceptibility of Alcaligenes xylosoxidans isolated from patients with cystic fibrosis. J Clin Microbiol 2001;39:3942-5.